Navigation Links
BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
Date:2/27/2013

ROCKVILLE, Md., Feb. 27, 2013 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the formation of its Commercial Relevance Advisory Board (CRAB). Members of the CRAB represent diverse business and academic organizations from throughout the region, such as venture capital firm New Enterprise Associates, Ernst & Young, the Howard Hughes Medical Institute, the University of Maryland (UMD), Johns Hopkins University, and leading biotechnology companies.

The CRAB will assist BHI in evaluating market-relevant research and product development opportunities as well as help determine the commercial applicability of emerging entrepreneurs, companies and their science or technology. BHI will utilize feedback from CRAB members as part of its due diligence process for establishing formal client relationships and potentially future investments.

CRAB members include:

  • Jesse  Baumgold, Principal, BioEnterprises, LLC
  • Dan Bednarik , Senior Director, MEU Operations, Intrexon Corporation
  • Judy Britz , Executive Director, Maryland Biotechnology Center
  • Steve Canaras, Partner, Ernst & Young
  • Edward Chan , NaviMed Capital
  • Martha Connolly , Director, Maryland Industrial Partnerships (MIPS), UMD
  • Tom Dann , Managing Director of Equity Funds, Maryland Venture Fund, Maryland State Department of Business & Economic Development
  • Brian Darmody , Associate Vice President for Research and Economic Development, UMD
  • Doug Doerfler , President & CEO, MaxCyte Inc.
  • Moustapha El Amine , Senior Director, Scientific Services, Emergent BioSolutions
  • Bill Enright , President & CEO, Vaxin Inc.
  • Elizabeth Good , Director, Ventures, Johns Hopkins University
  • Jim Hughes , Chief Enterprise and Economic Development Officer/Vice President at UMD Baltimore, & Director, UM Ventures
  • Rachel King , CEO, GlycoMimetics, Inc.
  • James Lee , Executive Vice President/CFO, Adventist Healthcare
  • Raj Malik, Co-Founder & CEO, Infusd
  • Ken Malone , Principal, Early Charm Ventures, LLC
  • Arumani Manisundaram, Director, Center of Connected Health, Adventist Healthcare
  • Chris Meenan , Director, Clinical Informatics, School of Medicine, UMD
  • Arkesh Mehta, CEO, Chikujee Therapeutics
  • Cheryl Moore , Executive Vice President & COO, Howard Hughes Medical Institute
  • Sara Nayeem , Principal, New Enterprise Associates
  • Jerry Parrott , Principal, Jerry Parrott LLC and Chair and President, Maryland Health Care Product Development Corporation
  • Joana Rosario , Principal, J. Rosario et Al, LLC
  • Rob Rosenbaum , President & Executive Director, TEDCO
  • Vin Singh , CEO, Next Healthcare, Inc.
  • Gayatri Varma , Executive Director, Office of Technology Commercialization, UMD

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.


'/>"/>
SOURCE BioHealth Innovation, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
2. Economic Alliance of Greater Baltimore Inks Business Partnership with BioHealth Innovation to Bring Health and Life Sciences Research to Market
3. BioHealth Innovation, Inc. Caps Next Phase Of Development With Move To New Headquarters And Addition Of Staff
4. Two Baltimore Business Leaders are BioHealth Innovation, Inc.s Newest Board Members
5. New Report: "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance" Now Available at Twease.org
6. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
7. Lucintel Performs Competitive Analysis on Top Five Global Consumer Electronic Companies
8. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
9. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
10. Cellular Dynamics Announces Commercial Launch of iCellĀ® Neurons for Neuroscience Drug Discovery
11. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):